Puma Biotechnology - Stock Price History | PBYI

Historical daily share price chart and data for Puma Biotechnology since 2021 adjusted for splits. The latest closing stock price for Puma Biotechnology as of September 27, 2021 is 7.12.
  • The all-time high Puma Biotechnology stock closing price was 275.07 on September 18, 2014.
  • The Puma Biotechnology 52-week high stock price is 14.14, which is 98.6% above the current share price.
  • The Puma Biotechnology 52-week low stock price is 6.48, which is 9% below the current share price.
  • The average Puma Biotechnology stock price for the last 52 weeks is 9.74.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Puma Biotechnology Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 10.0951 8.4300 14.5650 6.2800 10.2600 17.26%
2019 17.9948 21.6800 42.3700 6.5000 8.7500 -57.00%
2018 52.6096 92.6500 99.2500 20.0700 20.3500 -79.41%
2017 74.4849 31.5000 132.4500 29.0000 98.8500 221.99%
2016 42.5287 73.5400 73.5400 21.8700 30.7000 -60.84%
2015 140.9730 189.8600 249.7100 64.9700 78.4000 -58.58%
2014 154.7279 102.0600 275.0700 54.9900 189.2700 82.82%
2013 43.5442 19.0100 110.1000 18.9500 103.5300 452.16%
2012 15.1608 14.0000 22.6000 11.0000 18.7500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.290B $0.225B
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29